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Type 1 diabetes mellitusHyperglycaemia-related mitochondrial impairment is suggested as a contributor to skeletal muscle dysfunc-
tion. Aiming a better understanding of the molecular mechanisms that underlie mitochondrial dysfunction in
type 1 diabetic skeletal muscle, the role of the protein quality control system in mitochondria functionality was
studied in intermyoﬁbrillar mitochondria that were isolated from gastrocnemiusmuscle of streptozotocin (STZ)-
induced diabetic rats. Hyperglycaemic rats showed more mitochondria but with lower ATP production ability,
which was related with increased carbonylated protein levels and lower mitochondrial proteolytic activity
assessed by zymography. LC-MS/MS analysis of the zymogram bands with proteolytic activity allowed the iden-
tiﬁcation of an AAA protease, Lon protease; themetalloproteases PreP, LAP-3 andMIP; and cathepsin D. The con-
tent and activity of the Lon protease was lower in the STZ animals, as well as the expression of the m-AAA
protease paraplegin, evaluated by western blotting. Data indicated that in muscle from diabetic rats the mito-
chondrial protein quality control system was compromised, which was evidenced by the decreased activity of
AAA proteases, and was accompanied by the accumulation of oxidatively modiﬁed proteins, thereby causing
adverse effects on mitochondrial functionality.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are the center of fatty acid and glucose metabolism
[1,2] and thus are likely to be impacted by the impaired metabolism
related with diabetes mellitus [2–5], particularly evident in skeletal
muscle because of its high metabolic rate [4]. Indeed, skeletal muscle
mitochondrial dysfunction has already been linkedwith insulin depriva-
tion and/or resistance [6]. Dysfunctional mitochondria carry a greater
risk of futile ATP hydrolysis and enhanced reactive oxygen species
(ROS) generation [2,3,7], being mitochondrial respiratory chain one of
its main sources and mitochondrial proteins especially susceptible to
oxidative modiﬁcation [3,8]. When this damage cannot be repaired by
chaperones, defective proteins are targeted for degradation [7,9]. Selec-
tive proteolysis occurs in mitochondria in order to remove short-lived
regulatory proteins and to prevent the harmful accumulation of non-
native polypeptides. By degrading misfolded and non-assembled poly-
peptides, mitochondrial proteases perform quality control surveillancede gel electrophoresis; Anti-
ve phosphorylation; IMF, inter-
e 1 diabetes mellitus
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rights reserved.in the organelle [1,7,9]. Among the mitochondrial proteolytic systems
are the membrane-bound ATP-dependent proteases, namely m-AAA
proteases composed of Afg312 and paraplegin subunits, whichmediate
the breakdown of membrane proteins, Clp-like and Lon proteases that
are present in the matrix and HtrA2/Omi in the intermembrane space
[1,7,10–12]. Given the protective role of these mitochondrial proteases,
interest is unsurprisingly increasing in the literature aiming the under-
standing of the quality control surveillance mechanisms involved in
pathophysiological conditions, like neurodegenerative diseases, aging
[7], and cancer [13]. For instance, a correlation between decreased Lon
protein levels and increased ROS concentration was observed with in-
creasing age [14]. Although a clear association between defective mito-
chondrial oxidative phosphorylation (OXPHOS) and diabetes has already
been reported [2,3,5,6], the contribution of mitochondrial proteases to
the organelle's dysfunction secondary to this disease is far from being
understood.
The mitochondria's ability to adapt to hyperglycaemia depends on
cell type. Within myoﬁbers, mitochondria exist in two spatial distinct
populations according to their subcellular spatial arrangement. Sub-
sarcolemmal (SS) mitochondria are found beneath the sarcolemma,
and intermyoﬁbrillar (IMF) mitochondria are intermingled within the
myoﬁbrils [4,15,16]. Although similar in their central role in cellular
function,mitochondrial subpopulations demonstrate unique adaptative
capacities according to their different functional, compositional, and
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subjects, skeletalmuscle IMF contentwas lower and correlatedwith ab-
normal fuel utilization patterns [18]. Adhihetty et al. [19] reported a
greater rate of mtPTP openingwithin the IMF subpopulation in response
to ROS. A similar effect was observed byWilliamson et al. [20] in the car-
diac mitochondria of streptozotocin (STZ) rats andwas accomplished by
signiﬁcant changes in the levels of apoptotic proteins, which is sugges-
tive of an association between diabetes-related mitochondrial dysfunc-
tion and an enhanced apoptotic propensity of IMF mitochondria. These
ﬁndings suggest a greater susceptibility of IMF to hyperglycaemia, and
the need for a deeper examination of the molecular mechanisms that
underlie the spatial inﬂuence of the diabetic phenotype on mitochon-
drial dysfunction. Thus, the goal of our studywas to determinewhether
IMF mitochondrial protein quality control systems are affected by STZ-
induced hyperglycaemia and how they relate tomitochondrial dysfunc-
tion in skeletal muscle.
2. Materials and methods
2.1. Chemicals
Streptozotocin [N-(Methylnitrosocarbamoyl)-a-D-glucosamine] was
obtained from Sigma Chemical Co. (St Louis, MO, USA), and prepared
prior to use in 100 mM citrate, pH 4.5. All other reagents and chemicals
used were of highest grade of purity commercially available. Rabbit poly-
clonal anti-paraplegin antibody (cat. no. sc-135026) was obtained from
Santa Cruz Biotechnology, INC. (CA, USA). Rabbit polyclonal anti-mtTFA
antibody (cat. no. ab47548), rabbit polyclonal anti-mitoﬁlin antibody
(cat. no. ab48139), rabbit polyclonal anti-LONP1 (ab103809) and mouse
monoclonal anti-ATPB antibody (cat. no. ab14730) were obtained from
Abcam (Cambridge, UK). Rabbit polyclonal anti-DNP antibody was
obtained from DakoCytomation (Hamburg; Germany). Mouse monoclo-
nal MMP-9 (Clone 36020; cat.no.MAB936) was acquired from R&D sys-
tems (Minneapolis, USA) and rabbit polyclonal anti-UCP3 (U7757) was
obtained from Sigma. Secondary peroxidase-conjugated antibodies
(anti-mouse IgG and anti-rabbit IgG) were obtained from GE Healthcare
(Buckinghamshire, UK).
2.2. Animals
Twenty Wistar male rats (aged 6–8 weeks, weighing 200 g at the
beginning of the experiments)were used. During the experimental pro-
tocol, the animals were housed in collective cages (4 rats per cage) and
weremaintained in a roomat normal environment (21–24 °C; ~50–60%
humidity) receiving food and water ad libitum in 12 h light/dark cycles.
The animals were randomly divided into two groups (n=10 per group):
type 1diabetic group (T1DM)and control group (CONT). Housing and ex-
perimental treatment were in accordance with Guide for the Care and Use
of Laboratory Animals from the Institute for Laboratory Animal Research
(ILAR, 1996). The local Ethics Committee had approved the study and
the experimental procedures were complied with the current national
laws.
2.3. Induction and characterization of STZ-induced hyperglycemia
In order to induce hyperglycemia, one group of animals (T1DM)was
treated with a single intraperitoneal injection of Streptozotocin (STZ;
60 mg/kg), after a 16-h fasting period. Control animals were injected
with citrate solution. During the experimental period, weight wasmea-
sured and glucose concentration was determined in blood samples
collected from the tail vein with Glucocard (A. Menarini diagnostic).
Values were taken just before STZ administration and in the weeks after
until the end of the protocol. Animals were considered hyperglycemic
when, after feeding, blood glucose exceeded 250 mg/dl. After 4r months,
animals were sacriﬁced and gastrocnemius muscle was dissected out.
Small muscle portions were kept for TEM analysis with the remainingtissue used for the isolation of mitochondrial populations. Three pools of
muscles from 3 or 4 rats were performed for each experimental group.
2.4. IMF mitochondria isolation
The IMFmitochondriawere puriﬁed fromgastrocnemiusmuscle fol-
lowing the protocol described by Ferreira et al. [15], which is based on
tissue mechanical treatment and enzymatic digestion as previously
reported by Palmer et al. [21]. Muscle pools from each group were
simultaneously processed to avoid potential methodological bias. All
the procedures were performed on ice or below 4 °C. The muscle tissue
was washed three times with 20 mMMOPS, 110 mM KCl, 1 mM EGTA
(pH 7.5), minced with scissors and then incubated in the aforemen-
tioned buffer with 0.25 mg/mL trypsin (Promega, Wisconsin, USA).
After 25 min on ice, albumin fat-free (Sigma, St. Louis, MO, USA) was
added to a ﬁnal concentration of 10 mg/mL. The tissuewas subsequently
rinsed three times with buffer and then homogenized with a Potter ho-
mogenizer (Teﬂonpestle). An aliquot ofwhole homogenatewas separat-
ed for CS activity assay. Large cellular debris and nuclei were pelleted by
centrifuging for 5 min at 1000 ×g. A mitochondria enriched fraction was
obtained by centrifuging the supernatant for 20 min at 16,000 ×g and
re-suspending the pellet in a small volume of buffer (250 mM sucrose,
10 mM Tris–HCl, 0.1 mM EGTA (pH 7.4)). Pure IMF mitochondria
were then obtained by ultracentrifugation at 95,000 ×g for 30 min on
a density-gradient with 50% (v/v) Percoll. Two brown bands were ob-
served; the lower band corresponded to IMF mitochondria while the
upper band corresponded to SSmitochondria [15]. The IMFmitochondri-
al fraction was then washed twice and aliquoted for TEM analysis, BN-
PAGE, in-gel activity of complexes IV and V, spectrophotometric assay
of complexes III and V activities, immunoblot detection of paraplegin,
Lon, ATP synthase subunit β, mtTFA, UCP-3, mitoﬁlin, slot–blot of car-
bonyl content and MMP-9 and zymography/nLC-Maldi-MS/MS analysis
of mitochondrial proteases. Protein content was determined with RC
DC Protein Assay kit (Bio-Rad, Hercules, CA, USA) and mtDNA content
was quantiﬁed with QubitTM ﬂuorometer (Invitrogen, Carlsbad, CA,
USA).
2.5. Electron microscopic analysis
For morphological characterization, 75 μL of mitochondrial suspen-
sion of IMF mitochondria of each group was centrifuged at 7000 ×g for
10 min and the resulting pellet was processed as previously described
[15]. Ultra-thin (100 nm) sections were contrasted with uranyl acetate
and lead citrate for TEM analysis (Zeiss EM 10A).
2.6. Citrate synthase (CS) activity
The CS activity was measured in muscle homogenate and in IMF mi-
tochondria using the method proposed by Coore et al. [22]. In brief, the
CoASH released from the reaction of acetyl-CoA with oxaloacetate
was measured by its reaction with 5,5′-dithiobis-(2-nitrobenzoic acid)
(DTNB) at 412 nm(molar extinction coefﬁcient ε=13.6 mM−1 cm−1).
2.7. Respiratory chain complexes activities
For spectrophotometric determinationof respiratory chain complexes
activity (III and V), themitochondrial fractions were disrupted by a com-
bination of freeze–thawing cycles in hypotonicmedia (25 mMpotassium
phosphate, pH 7.2) to allow free access to substrates for all assays [23].
CIII activity wasmeasured at 550 nm (ε=19mM−1 cm−1) in a reaction
mixture containing reaction buffer (50 mMpotassiumphosphate, pH 7.4,
5 mM MgCl2, and 1 mg/ml BSA), 1 μg of sonicated mitochondria, 20 μM
rotenone, 2 mMKCN, 0.2 mMATP, and 40 μMcytochrome c. The reaction
was initiated by the addition of 100 μM decyl benzoquinol with or with-
out 7.4 μM antimycin A. The ﬁnal rate was measured by subtracting the
antimycin A-insensitive rate from the rate without the addition of the
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Simon et al. [25]. The phosphate produced by hydrolysis of ATP re-
acts with ammonium molybdate in the presence of reducing agents
to form a blue-color complex, the intensity of which is proportional to
the concentration of phosphate in solution. Oligomycin was used as an
inhibitor of mitochondrial ATPase activity.
A Multiskan GO Microplate Spectrophotometer (Thermo Scientiﬁc)
was used for respiratory chain complexes activities measurement,
which was performed at 30 °C.
2.8. Blue-native PAGE separation of mitochondria membrane complexes
BN-PAGE was performed using the method described by Schägger
and von Jagow [26] with minor modiﬁcations. IMF mitochondria
(400 μg of protein) from each group (duplicate of n=3) were pelleted
by centrifugation at 20,000 ×g for 10 min and then resuspended in
solubilization buffer (50 mM NaCl, 50 mM Imidazole, 2 mM α-amino
n-caproic acid, 1 mM EDTA pH 7.0) with 1% (w/v) digitonin. After
10 min on ice, insoluble material was removed by centrifugation at
20,000 ×g for 30 min at 4 °C. Soluble components were combined with
0.5% (w/v) Coomassie Blue G250, 50 mM α-amino n-caproic acid, 4%
(w/v) glycerol and separated on a 4–13% gradient acrylamide gradient
gel with 3.5% sample gel on top. Anode buffer contained 25 mM
Imidazole pH 7.0. Cathode buffer (50 mM Tricine and 7.5 mM Imidazole
pH 7.0) containing 0.02% (w/v) Coomassie Blue G250 was used during
1 h at 70 V, the time needed for the dye front reach approximately one-
third of the gel. Cathode buffer was then replaced with one containing
only 0.002% (w/v) Coomassie Blue G250 and the native complexes
were separated at 200 V for 4 h at 4 °C. A native protein standard
HMW-native marker (GE Healthcare, Buckinghamshire, UK) was used.
The gels were stained with Coomassie Colloidal (0.12% (w/v) Coomassie
Blue G250 prepared in 20% methanol) after 1 h ﬁxation in a solution of
10% acetic acid and 40% methanol. Gels were then destained with 25%
methanol and scanned with Gel Doc XR System (Bio-Rad, Hercules, CA,
USA). Band detection, quantiﬁcation and matching were performed
using QuantityOne Imaging software (v4.6.3, Bio-Rad).
2.9. In-gel activity of complexes IV and V
The histochemical staining assays of complexes IV and Vwere deter-
mined using the methods described by Zerbetto et al. [27] with minor
modiﬁcations. Complex IV-speciﬁc heme stain in BN-PAGE gels was de-
termined using 10 μL horse heart cytochrome c (5 mM) and 0.5 mg dia-
minobenzidine (DAB) dissolved in 1 mL 50 mM sodium-phosphate, pH
7.2. The reaction was stopped by 50% (v/v) methanol, 10% (v/v) acetic
acid, and the gels were then transferred to water. ATP hydrolysis activity
of complex V was analyzed by incubating the native gels with 35 mM
Tris, 270 mMglycine buffer, pH 8.3 at 37 °C, that had been supplemented
with 14 mM MgSO4, 0.2% (w/v) Pb(NO3)2, and 8 mM ATP. Lead phos-
phate precipitation that is proportional to the enzymatic ATP hydrolysis
activity was stopped by 50% (v/v) methanol (after 30 min), and the gels
were then transferred to water.
2.10. Analysis of mitochondrial proteolytic activity analysis through
gelatine zymography
Zymography assays were performed according to Vitorino et al. [28]
with minor alterations. Brieﬂy, the zymography was performed using a
10% SDS-PAGE separation gel with 0.1% of gelatin. Forty micrograms of
IMF mitochondria from each group was incubated on charging buffer
(100 mM Tris pH 6.8, 5% SDS, 20% glycerol, 0.1% bromophenol blue) for
10 min on ice, in a proportion of 1:1 (v/v). After the run, the gelswere in-
cubated in renaturation buffer (2.5% Triton X-100) for 30 min, with soft
agitation. Then, the zymogramgelswere changed to a development buff-
er (50 mM Tris, 5 mMNaCl, 10 mMCaCl2, 1 μmZnCl2, 0.02% (v/v) Triton
X-100, pH 7.4) for more 30 min, also with soft agitation. Finally, the gelswere changed to a new development buffer, and incubated overnight at
37 °C. For speciﬁc inhibition studies zymograms were incubated in the
presence of 10 mMEDTA or 1 mMPMSF. The zymography gelswere sta-
ined with 0.12% (w/v) Coomassie Blue G250 prepared in 20% methanol,
after 1 h ﬁxation in a solution of 10% acetic acid and 40% methanol. Gels
were then destained with 25% methanol and scanned with Gel Doc XR
System (Bio-Rad).
2.11. Proteases identiﬁcation by nLC-MALDI-MS/MS analysis
The zymography bands that showedproteolytic activitywere excised
manually from the gel andwashedwith 25 mMof ammoniumbicarbon-
ate/50% acetonitrile and dried under vacuum (SpeedVac® Plus SC 210 A,
Thermo Savant, USA). The dried gel pieceswere rehydratedwith 25 μL of
10 μg/mL trypsin in 50 mM ammonium bicarbonate and digested over-
night at 37 °C. Tryptic peptides were extracted from the gel with formic
acid andwere then dried in a vacuum concentrator and re-suspended in
a 10 μL of a 50% acetonitrile/0.1% formic acid solution.
Separation of tryptic peptides by nano-HPLC was performed on
themodule separation Ultimate 3000 (Dionex, Amsterdam), using a cap-
illary column (Pepmap100, 3 μmparticle size; 0.75 μminternal diameter;
15 cm length). A gradient was used from the A solvent–H2O/acetonitrile/
triﬂuoracetic acid (95:5:0.045 v/v/v)—to the B solvent—H2O/acetonitrile/
triﬂuoracetic acid (20/80/0.04 v/v/v). The separation was performed
using a linear gradient (5–55% B solution, for 30min, 55–80% B solution
for 10 min and 80–5% B solution for 5 min), each one with a ﬂow of
0.3 μL/min. The eluted fractions were applied directly on a MALDI plate
using an automatic fraction collector Probot (LcPackings).
The mass spectra of the peptides resulted from the proteins tryptic
digestion and separated through HPLC, were obtained with a mass
spectrometer MALDI-TOF/TOF (4800 Proteomics Analyzer, Applied
Biosystems, Foster City, CA, USA), in reﬂectron positive mode and
obtained in the mass interval between 700 and 4500 Da, with 850 laser
shots. A data-dependent acquisition method was created to select the
16 most intense peaks in each sample spot for subsequent tandem
mass spectrometry (MS/MS) data acquisition, excluding those from ma-
trix, due trypsin autolysis or acrylamide peaks. The internal standard
Glu-Fib peak (m/z 1570.68 Da) was used as internal calibration. Spectra
were processed and analyzed by Global Protein Server (GPS) Worksta-
tion (Applied Biosystems, Foster City, CA, USA), which uses internal Mas-
cot software (v2.1.0, Matrix Science, London, UK). Searches were done
against the UniProtKB/Swiss-Prot (UniProt release 2011_01) rodentia
protein databasewith trypsin speciﬁcity (twomissed cleavages allowed),
carboxyamidomethylation and oxidized methionine as variable modiﬁ-
cations. Precursor ion and fragment ion mass tolerances were 20 ppm
and 0.3 Da, respectively.
2.12. Western blotting analysis
Equivalent amounts of mitochondrial protein of each group were
electrophoresed on a 12.5% SDS-PAGE as described by Laemmli [29].
Gels were blotted onto a nitrocellulose membrane (Whatman®, Protan)
in transfer buffer (25 mM Tris, 192 mM glycine, pH 8.3 and 20% metha-
nol) for 2 h (200 mA). Then, nonspeciﬁc binding was blocked with 5%
(w/v) dry nonfat milk in TBS-T (100 mM Tris, 1.5 mM NaCl, pH 8.0 and
0.5% Tween 20) and the membrane was incubated with primary anti-
body diluted 1:1000 in 5%w/v nonfat drymilk in TBS-T (anti-paraplegin,
anti-Lon, anti-ATPB, anti-UCP3, anti-mitoﬁlin or anti-mtTFA) for 2 h at
room temperature, washed and incubated with secondary with horse-
radish peroxidase-conjugated anti-mouse or anti-rabbit (GE Healthcare),
respectively. Immunoreactive bands were detected by enhanced chemi-
luminescence ECL (AmershamPharmacia Biotech) according to theman-
ufacturer's procedure and images were recorded using X-ray ﬁlms
(Kodak Biomax Light Film, Sigma, St. Louis, MO, USA). The ﬁlms were
scanned in Molecular Imager Gel Doc XR+System (Bio-Rad) and ana-
lyzed with QuantityOne software (v 4.6.3 Bio-Rad). Protein loading was
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get has been described so far. A representative stained western blot is
presented as supplementary data (Fig. S2A).
2.13. Slot blot analysis
For the protein carbonyl derivates assay, a given volume (V)
of the sample containing 20 μg of protein was derivatized with
2,4-dinitrophenylhydrazine (DNPH). Brieﬂy, the sample was mixed
with 1 V of 12% sodium dodecyl sulphate, 2 V of 2 mM DNPH/10%
triﬂuoroacetic acid, followed by 30 min of incubation in the dark, after
which 1.5 V of 2 M Tris-base/18.3% of β-mercaptoethanol was added
for neutralization. After diluting the derivatized proteins in Tris buffered
saline to obtain a ﬁnal concentration of 0.001 μg/μL, a 100 μL volume
was slot-blotted into a nitrocellulose membrane.
For MMP-9 expression evaluation, whole IMF mitochondria sam-
ples were diluted in Tris buffered saline (TBS) to obtain a ﬁnal protein
concentration of 0.001 μg/μL and a volume of 100 μL was slot-blotted
into a nitrocellulose membrane (Whatman®, Protan ®).
The slot-blot membranes were blocked with 5% (w/v) dry nonfat
milk in TBS-T for 30 min and then incubated for 30 min with primary
antibody (anti-MMP-9 or anti-DNP antibody) diluted 1:1000 in 5%
w/v nonfat dry milk in TBS-T. The membranes were washed three
times (10 min each)with TBS-T and incubated for 30 minwith a solution
of horseradish-conjugated anti-mouse or anti-rabbit antibody (GE
Healthcare), respectively, in a dilution of 1:1.000. Detection was carried
out with enhanced chemiluminescence (Amersham Pharmacia Biotech)
according to the manufacturer's procedure and images were recorded
using X-ray ﬁlms (Kodak Biomax Light Film, Sigma, St. Louis, MO, USA).
The ﬁlms were scanned in Molecular Imager Gel Doc XR+System
(Bio-Rad) and analyzed with QuantityOne software (v 4.6.3 Bio-Rad).
Protein loading was controlled by Ponceau S staining. A representative
stained slot blot is presented as supplementary data (Fig. S2B).
2.14. Statistical analysis
The results are presented as mean±SD for each group experimental.
The Kolmogorov–Smirnov test was used to test normality of distribution
for all data. Since all variable were normal distributed, signiﬁcant dif-
ferences between the two groups were evaluated with the unpaired
Student's t-test. Statistical Package for the Social Sciences (SPSS Inc,
Chicago, IL, USA, version 12.0) was used for all analyses. A p value b0.05
was considered signiﬁcant.
3. Results
Four months after STZ administration, body and gastrocnemius mus-
cle weights declined signiﬁcantly by 43% and 30% (pb0.0001; Table 1),
respectively. Blood glucose concentration levels were remarkably higher
in T1DM than in the control rats (pb0.01), which is indicative of pancre-
atic β-cell destruction. The high blood HbA1c content observed in STZ-
treated rats (pb0.01; Table 1) corroborated the hyperglycemia proﬁle.
During the experimental protocol, polyuria and polydipsia were noticed
in the T1DM rats, thereby emphasizing the diabetic condition.
IMFmitochondria were obtained from the gastrocnemius via a differ-
ential centrifugation protocol followed by Percoll centrifugation formito-
chondria puriﬁcation, as conﬁrmed by TEM (Fig. S1). No fragmentedTable 1
Characterization of animals' response to STZ administration.
Experimental group Body weight (g) Muscle weight (g) Muscle/b
CONT 437.1±58.4 5.69±0.04 13.03±0
T1DM 251.0±43.1*** 3.99±0.88** 15.90±0
Values are expressed as mean±standard deviation. ***pb0.0001 vs. Control; ** pb0.01 vs Cmembranes or any kind of debris was observed. Larger amplitude of
mitochondria size was noticed in T1DM group. A signiﬁcantly higher
mtDNA-to-musclemass ratio andmitochondrial protein-to-musclemass
ratio was also observed in the diabetic rats (pb0.05; Table 2), suggestive
of an increased IMF mitochondrial content in the T1DM rats. Although
in higher amount, IMFmitochondria seem less functional in the gastroc-
nemius of diabetic animals considering the signiﬁcant decrease in CS ac-
tivity (by 42%). Lower CS activity was also detected in thewholemuscle
homogenate (Table 2).
The analysis of the overall BN-PAGE band pattern revealed no qual-
itative differences of OXPHOS complexes organization among groups
(Fig. 1). However, the OD quantitative proﬁle of the BN-PAGE revealed
a 15% decreased in the amount of complex III in T1DM as compared to
the control group. No signiﬁcant differences in the other OXPHOS
complexes' levels were observed (Fig. 1D). Western blotting analysis
of the ATP synthase subunit beta was performed in order to validate
the OXPHOS proteins' expression proﬁle observed and no differences
were noticed between CONT and T1DM groups (Fig. 1E). In order to
evaluate the OXPHOS functionality, the in-gel activity of complexes IV
and V was determined. This analysis showed a decreased activity of
these OXPHOS complexes in the T1DM group, which was signiﬁcant
for ATP synthase (pb0.01; Fig. 1A). The respiratory chain functionality
was also spectrophotometrically assessed by determining the activity
of respiratory complexes III and V. The results revealed a signiﬁcant de-
crease in ATP synthase activity in T1DM rats (pb0.0001; Table 3),which
supports the in-gel activity data. The activity of ubiquinol-cytochrome c
reductase was also decreased, though with no statistical signiﬁcance.
Zymography analysis of IMF mitochondria revealed an overall decrease
in proteolytic activity in the T1DM group. The densitometric evaluation
(Fig. 2B) displayed six common bands in the zymograms for the control
and diabetic animals. Two of these bands, i.e., one with approximately
15 kDa (band 6) and other with approximately 40 kDa (band 5),
showed higher activities. To determine the protease classes present in
each band, zymo gels were incubated with different inhibitors (i.e.,
EDTA—metalloproteinase inhibitor and PMSF—serine protease inhibi-
tor) at their maximum effective concentration. The most outstanding
observation from the comparison of zymo gels C, D, and E (Fig. 2) was
the predominance of serine proteases. However, PMSF only moderately
inhibited the protease activity observed in band 6 (approximately 55%),
thereby suggesting the presence of other protease classes in the same
band. Using LC-MS/MS for the identiﬁcation of the mitochondrial prote-
ases in each band, the predominance of serine proteases was conﬁrmed;
more speciﬁcally the Lon protease was identiﬁed in bands 1, 5, and 6
(Table 4). The intact protease was recognized in band 1, which corre-
sponds to the molecular weight of this AAA protease, with the nine
peptides identiﬁed distributed for the protein sequence, namely in the
AAA+module (residues 515–681; involved in ATP hydrolysis and in pro-
tein substrate remodeling), and in the proteolytic domain (residues
705–959) (based onMEROPS). Fragments of this proteasewere identiﬁed
in bands 5 and 6, with a predominance of the N-terminus from the main
sequence. One of the peptides from the Lon protease fragment identiﬁed
in band 5 is located in the AAA+module whereas the two peptides from
the fragment identiﬁed in band 6 do not correspond to the AAA+module
neither to the proteolytic domain (Fig. S3), despite the high proteolytic
activity observed in the zymo gels. Presequence protease (PreP), an
ATP-independent protease involved in the removal of free targeting pep-
tides [30], was also identiﬁed by nanoLC-MS/MS in band 1. The identiﬁed
18 peptides of this clearing protease are distributed all over the proteinody weight ratio (mg g−1) Glycemia (mg dL−1) HbA1c (% total Hb)
.001 66.3±15.0 3.96±0.80
.006 577.1±234.0*** 6.28±1.12***
ONT.
Table 2
Effects of STZ administration in mitochondrial protein content, mtDNA concentration and citrate synthase (CS) activity in gastrocnemius muscle and in IMF mitochondria.
Experimental group Protein/mtDNA
(μg g−1)
mtDNA/muscle weight
(μg g−1)
Protein/muscle weight
(mg g−1)
Whole muscle CS
(nmol mg−1 min−1)
Mitochondria CS
(nmol mg−1 min−1)
CONT 0.52±0.552 0.55±0.056 0.28±0.006 93.2±18.9 139.7±43.7
T1DM 0.66±0.079 0.941±0.371* 0.63±0.293* 79.4±3.5* 81.4±18,2**
Values are expressed as mean±standard deviation. * pb0.05 vs CONT; **pb0.01 vs CONT
1193AI. Padrão et al. / Biochimica et Biophysica Acta 1822 (2012) 1189–1197sequence (Table 4). The intact mitochondrial intermediate peptidase
(MIP) was detected in band 2 of the zymo gel and the metallopeptidase
cytosol aminopeptidase, also called leucine aminopeptidase (LAP-3),
was identiﬁed in band 3. Typically associated with lysosomes, cathepsin
D was also detected in the IMF mitochondria by zymography/LC-MS/
MS (band 4; Fig. 2 and Table 4).
Based on OD density analysis and considering bands 5 and 6, the
ones with higher proteolytic activity, a decrease of 28% and 47%, re-
spectively, was observed in the T1DM zymo gels. The overall analysis
of the mitochondrial proteolytic activity suggests an impairment of Lon
protease activity in diabetic animals. To support these data, the Lon
expression was assessed by western blotting, and a signiﬁcant down-
regulation was observed in diabetic animals (Fig. 3A). The expression
of other AAA proteases, speciﬁcally m-AAA paraplegin, was also evalu-
ated (Fig. 3B). The western blot analysis of this protease showed a 2.5
fold decrease in the IMF of T1DM rats, as compared to the CONT group
(pb0.0001). Considering the moderated inhibitory effect of EDTA on
the proteases' activity observed by zymography and previous studies
that identiﬁed MMP-9 in mitochondria [31], the expression of this MMP
was assessed by slot-blot (Fig. 3C). Signiﬁcantly lower expression values
were observed in the IMF mitochondria of diabetic rats (69%; pb0.01).
The expression of other mitochondrial proteins was also analyzed.
The western blot analysis of the membrane protein mitoﬁlin revealed
two distinct bands corresponding to the described mitoﬁlin isoforms
(with ~87 kDa and ~89 kDa). For the present study, only the overall OD
valuewas considered, which corresponds to the sumof theODvalues of
the individual bands. The expression levels of thismitochondrial protein,Fig. 1. Evaluation of the respiratory chain structural organization. (A) Representative imag
presented a semi-quantitative analysis of in-gel activity of both complexes. (B) Representa
solved by Blue Native Polyacrylamide Gel Electrophoresis for type 1 diabetic group (T1DM)
sent on the right. (D) Densitometric analysis of BN-PAGE showing a signiﬁcant decrease in
blotting. A representative immunoblot is presented above the graph. Values are expressedwhich is involved in organelle structure maintenance, signiﬁcantly de-
creased in T1DM rats (pb0.01; Fig. 4A). Long-term hyperglycemia also
induced a signiﬁcant decrease of 20% in the expression of the mitochon-
drial transcriptional factormtTFA (Fig. 4B), which indicates the impaired
regulation of mtDNA gene expression in IMF mitochondria. Concomi-
tantly, a signiﬁcant increase of the uncoupling protein UCP3 was ob-
served in T1DMmitochondria (pb0.01; Fig. 4C).
To evaluate the effect of T1DM on mitochondrial proteins suscep-
tibility to oxidative damage, the total carbonyl content was measured
by slot blot after derivatization with dinitrophenylhydrazine. A signiﬁ-
cant increase of 21% (pb0.05) in the total carbonyl levels was noted in
the T1DMgroup as comparedwith CONTgroup (Fig. 4D). Being aconitase
particularly susceptible to oxidation under pathophysiological condi-
tions [32,33] and a known substrate of Lon protease [34], oxidatively
modiﬁed amino acid residues were searched by SDS-PAGE followed by
nano-LC-MS/MS analysis. Among the more prevalent oxidative modiﬁ-
cations, we found pyro-Glu (Fig. S4), thereby further supporting the
T1DM-related higher susceptibility of mitochondrial proteins to oxida-
tive damage.
4. Discussion
The aim of the present study was to gain more insight into the role of
themitochondrial protein quality control (PQC) system todiabeticmyop-
athy by studying skeletal muscle mitochondria from STZ rats, an animal
model of type 1 diabetes. T1DM rats exhibited a remarkable hyperglyce-
mia throughout the 4 months of the experimental period due to insuline of histochemical staining of in-gel activity of complexes IV and V. On the left side is
tive image of supramolecular architecture of mitochondrial membrane complexes re-
and control group (CONT). (C) An overlap of the density variation for both lanes is pre-
complex III content in T1DM. (E) ATP synthase beta expression evaluated by western
as mean±standard deviation. (**pb0.01 vs CONT).
Table 3
Effects of STZ administration in OXPHOS complexes III and V activities of IMFmitochondria.
Experimental group Ubiquinol cytochrome c
reductase (μmol/mg/min)
ATP synthase
(μmol Pi/min/mg)
CONT 3.72±1.24 14.36±1.80
T1DM 3.02±0.52 6.04±2.40***
Values are expressed as mean±standard deviation. ***pb0.0001 vs CONT.
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long-term hyperglycemia (Table 1)was associatedwith reduced IMFmi-
tochondrial ability to produce ATP (Table 3 and Fig. 1) in a similar way as
previously reported [5,6,35,36], and with high levels of UCP3 (Fig. 4C),
which seems to be involved in mitochondrial membrane potential dis-
sipation to protect against ROS production [37]. UCP3 overexpression
was already reported in cardiac mitochondria from type 1 diabetic
Akita mice [38]. Being around 80% of the total mitochondrial muscle
content [19] and specialized toward energy production for contractile
activity [15], focus was given to the IMF subpopulation driven muscle
adaptation to type 1 diabetes.
As a source for the formation of ROS, mitochondria themselves are a
prime target of oxidative modiﬁcations. ROS can directly perturb protein
folding by modifying amino acids, or indirectly by introducingmutations
in genes encoded by mitochondrial or nuclear DNA [1]. The resulting ac-
cumulation of orphanedmitochondrial complex subunits or toxic protein
aggregates can generate an overwhelming load of misfolded mitochon-
drial proteins [1,7], which compromises the signalling networks in this
organelle and consequently in the whole cell [7]. The increased amount
of carbonylated proteins observed in diabetic mitochondria (Fig. 4D) re-
ﬂects a disease-related higher susceptibility of mitochondrial proteins
to oxidative damage as previously reported [39]. Due to the covalent na-
ture of the protein modiﬁcations generated by ROS, the proteolytic re-
moval of damaged peptides is a major protective process of the PQC
system under oxidative stress [40]. The typical effector enzymes of pro-
tein homeostasis are molecular chaperones and proteases [40]. To evalu-
ate the T1DM effect on mitochondrial proteolysis, gelatin zymography of
pure IMF fractions was performed (Fig. 2). The inhibitory effect of PMSF
in the protease activities observed in zymo gels highlights the involve-
ment of mitochondrial serine proteases in the mitochondrial PQC. In
the zymogram bands with higher proteolytic activity we identiﬁed by
LC-MS/MS the Lon protease, a serine protease with a recognized crit-
ical role in the removal of oxidized protein [1,7,13]. This AAA protease
exists in the matrix with the function of degrading misfolded and non-Fig. 2. Effect of 4 months of STZ administration in the mitochondrial proteolytic activity of ga
with noticeable proteolytic activity (bands 5 and 6). An overlap of densitometric variation
activity of bands 5 and 6 is presented in (A). Representative image of the zymo gels in the
(EDTA). Values are expressed as mean±standard deviation. (*pb0.01 vs CONT).assembled proteins and peptides, including denatured and carbonylated
proteins, being aconitase as a good example [41]. In addition to Lon,
other ATP-dependent serine proteases play a crucial role in the mito-
chondrial PQC. For instance, the breakdown ofmitochondrial membrane
proteins is mediated by membrane-bound AAA proteases [1,42]. The
lower expression levels of the paraplegin observed in T1DM mitochon-
dria (i.e., 63%) suggest that the decreased activity of m-AAA may also
contribute to the accumulation of oxidatively damaged proteins and
might compromise the biogenesis of some nuclear-encoded mitochon-
drial proteins [5]. Defects in PQC systems have been implicated in certain
pathological conditions [7]. Nevertheless, to date, no previous studies
have evaluated the involvement of AAAproteases in diabetes-relatedmi-
tochondrial dysfunction in striated muscle.
Although no notorious inhibitory effect of EDTA was observed in
zymograms, three metalloproteases were identiﬁed by LC-MS/MS. The
diminished activity of the mitochondrial PreP with the consequent accu-
mulation of toxic free presequences that are a result of the action ofmito-
chondrial processing peptidase over precursor proteins was previously
reported in Alzheimer disease. If not removed, these free presequences
penetrate the mitochondrial inner membrane, dissipate membrane po-
tential and uncouple respiration, thereby compromising mitochondrial
functionality [30]. Another mitochondrial metalloproteinase identiﬁed
by zymography-LC/MS/MS was MIP, a matrix peptidase involved in the
proteolytic processing of speciﬁc subsets of nuclearly andmitochondrialy
encoded precursor polypeptides [43]; however, no activity variations
were noticed. The metalloprotease LAP-3 was also identiﬁed, but no
T1DM-induced activity alterations were observed. To the best of our
knowledge, this is the ﬁrst study where a LAP member was identiﬁed in
mitochondria. Based on the broader speciﬁcity of LAPs, it seems difﬁcult
to predict its role inmitochondrial structure or functionality. The identiﬁ-
cation of traditionally extracellular or cytoplasmic metalloproteases in
mitochondria is not original, beingMMPs good examples. Indeed, the no-
tion of the intracellular location ofMMPs has already been suggested [44]
and the presence of MMP-2 and MMP-9 in cardiac mitochondria was
reported by others [31]. Although not identiﬁed by zymography,
MMP-9 was detected by slot-blot analysis and a T1DM-relatedmodula-
tion of its expression levelswas identiﬁed (Fig. 3C). TheMMPactive site is
bound with nitric oxide, and once activated, a decrease in eNO bio-
availability with an increased generation of peroxynitrite occurs [31]. No
association betweenMMP-9 activation andROS productionwas observed
in the present study considering the observed T1DM-related decrease of
MMP-9 and the increased carbonyl group content. Nevertheless, the
mechanisms involved in mtMMP activation and its physiological conse-
quences are currently not clearly understood.strocnemiusmuscle. (C) Representative image of the zymography evidencing two bands
for CONT and T1DM lanes is presented in (B). Semi-quantitative analysis of proteolytic
presence of inhibitors for (D) serine proteases (PMSF) and for (E) metalloproteinases
Table 4
List of proteases identiﬁed by zymography-LC-MS/MS. The information regarding protein accession number and name, protein molecular weight (M.W.), isoelectric point (pI) of the protein, peptide count, protein score, % coverage and
peptide sequence is presented.
Band
no.
Protein name Accession
number
Total ion
score
Total ion
score C.I. %
Protein
MW
Protein
PI
Peptide
count
% coverage Best peptide sequence Start
sequence
position
End
sequence
position
Ion
score
Ion
score
C.I. %
Ion
score
C.I. %
Calculated
mass
Observed
mass
1 NPVFPR 120 125 40,54 99,51 729,40 729,43
IAYTFAR 806 812 38,14 99,15 841,46 841,47
YLVPQAR 663 669 35,65 98,48 846,48 846,50
LAQPYVGVFLK 147 157 55,88 99,99 1234,72 1234,72
Lon protease homolog,
mitochondrial
LONM_RAT 470,77 100 105726,25 6,17 9 11,00 VLEFIAVSQLR 491 501 79,10 100,00 100,00 1274,75 1274,75
NLQKQVEKVLR 701 711 8,40 0,00 1354,82 1354,74
LALLDNHSSEFNVTR 435 449 81,45 100,00 1715,87 1715,86
TENPLVLIDEVDKIGR 572 587 115,85 100,00 1810,99 1810,98
IVSGEAQTVHVTPENLQDFVGKPVFTVER 717 745 16,94 0,00 3196,66 3196,68
NPVFPR 120 125 40,54 99,51 729,40 729,43
IAYTFAR 806 812 38,14 99,15 841,46 841,47
YLVPQAR 663 669 35,65 98,48 846,48 846,50
LAQPYVGVFLK 147 157 55,88 99,99 1234,72 1234,72
VLEFIAVSQLR 491 501 79,10 100,00 1274,75 1274,75
NLQKQVEKVLR 701 711 8,40 0,00 1354,82 1354,74
LALLDNHSSEFNVTR 435 449 81,45 100,00 1715,87 1715,86
TENPLVLIDEVDKIGR 572 587 115,85 100,00 1810,99 1810,98
Presequence protease,
mitochondrial
PREP_MOUSE 256,72 100 117297,23 6,76 18 17,95 IVSGEAQTVHVTPENLQDFVGKPVFTVER 717 745 16,94 0,00 99,99 3196,66 3196,68
YLHLAR 76 81 26,26 86,83 772,45 772,47
FLHTEIR 893 899 29,49 93,74 915,50 915,53
IFSQHLQNK 216 224 39,76 99,41 1114,60 1114,61
NNLFSVQFR 85 93 0,58 0,00 1124,58 1124,51
ELDFWQEGWR 174 183 58,25 99,99 1365,62 1365,62
TVPYADPDHASLK 871 883 48,95 99,93 1413,70 1413,70
LVTDPTFKPCQMK 841 853 3,37 0,00 1507,76 1507,81
KLVTDPTFKPCQMK 840 853 2,93 0,00 1635,86 1635,80
ALIESGLGTDFSPDVGYNGYTR 364 385 47,13 99,89 2332,11 2332,10
IGHPEQAFR 125 133 37,23 98,96 99,99 1054,54 1054,56
HLLPEHIQHHFAR 230 242 55,83 99,99 1634,87 1634,86
SAGVDDQENWHEGKENIR 105 122 129,69 100,00 100.00 2083,94 2083,92
DKDDDVPQFTSAGENFNK 44 61 108,81 100,00 2026,90 2026,88
TLIEFLLR 506 513 59,95 100,00 1004,61 1004,64
NIFSFYLNR 222 230 37,40 99,02 100,00 1173,53 1173,52
2 Mitochondrial intermediate
peptidase
MIPEP_RAT 93,06 100 80621,32 6,06 2 2,82 LGGQNYELHPEK 337 348 62,07 100,00 1384,69 1384,69
3 Cytosol aminopeptidase AMPL_RAT 298,56 100 56114,68 6,77 3 7,90 NLQKQVEKVLR 701 711 7,32 0,00 100,00 1354,82 1354,75
4 Cathepsin D CATD_RAT 99,47 100 44651,89 6,66 2 4,70 TENPLVLIDEVDKIGR 572 587 65,56 100,00 1810,99 1810,98
5 Lon protease homolog,
mitochondrial
LONM_RAT 71,70 100 105726,25 6,17 2 2,63 NPVFPR 120 125 38,90 99,28 99,28 729,40 729,43
6 Lon protease homolog,
mitochondrial
LONM_RAT 90,46 100 105726,25 6,17 2 1,05 RIHISR 201 206 31,72 96,26 96,26 781,48 781,50
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Fig. 3. Effect of 4 months of STZ administration in the AAA proteases Lon (A) and paraplegin (B) expression evaluated by western blotting and in the MMP-9 expression evaluated
by slot-blot (C). Representative immunoblots are presented above the respective graph. Values are expressed as mean±standard deviation. (**pb0.01vs CONT; ***pb0.001vs
CONT).
1196 AI. Padrão et al. / Biochimica et Biophysica Acta 1822 (2012) 1189–1197Besides serine and metalloproteases, cathepsin D was also identiﬁed
by zymography/LC-MS/MS. This lysosomal proteasewas already detected
by 2DE-MS/MS in the matrix of pure IMF fractions isolated from gas-
trocnemius [15]. Though its role in mitochondria homeostasis is still
to be addressed, cathepsin D seems to trigger amitochondrial apoptotic
cascade [45]. Regarding its contribution to diabetes complications, a de-
creased activity of cathepsin D in the whole heart tissue of STZ animals
was previously reported [46]. In thepresent study, no T1DM-related alter-
ation in themitochondrial activity of this aspartyl proteasewas observed.
The limited capacity of the PQC system observed in diabetic mito-
chondria might explain the disease-induced alterations in mitochon-
drial biogenesis, which controls the number, mass and function of this
organelle [1]. Unlike previous studies that reported a diabetes-related
decrease of mitochondrial mass [39,47], we observed an increase in IMF
mitochondria based on mtDNA-to-muscle mass ratio (Table 2), a rough
marker of mitochondrial content [15]. Though present in apparently
higher number, IMFmitochondria showed a lower citrate synthase activ-
ity, thereby corroborating previous studies that identiﬁed compromised
activity of the Krebs cycle enzymes in diabetes [39,47].Mitochondrial bio-
genesis requires a coordinated control of nuclear and mitochondrial
genes encoding mitochondrial proteins. Tfam plays a critical role in
nuclear-mitochondrial interactions [48], and we found that it was
down-regulated in diabetic muscle (Fig. 4B). This nuclear encodedFig. 4. Effect of 4 months of STZ administration in mitoﬁlin (A), mtTFA (B), UCP3 (C) expre
noblots are presented above the corresponding graph. Values are expressed as mean±stantranscription factor is one of the most important proteins that controls
mtDNA replication and transcription [49], thereby regulating the expres-
sion of mitochondrial proteins required for ATP synthesis [4], which was
impaired in diabetic animals. Kanazawa et al. [50] did not detect differ-
ences in the expression levels of Tfam in control and diabetic rat hearts,
but they observed a decreased binding activity related with insufﬁcient
RNA polymerase access to the initiation site of the transcription. Con-
comitant with lower Tfam levels in T1DM mitochondria, alterations of
mitoﬁlin content were also observed (Fig. 4A). The inner mitochondrial
membrane protein mitoﬁlin has been suggested to control mitochondri-
al cristae organization, and its down-regulationwas previously related to
a drastic change in the organization of the inner membrane [51]. So, the
T1DM-related mitochondrial impairment might be at least partially re-
lated to the destabilization of the inner membrane organization, where
OXPHOS complexes are harbored. Several studies reported morphologi-
cal disturbances in STZ rats, including an increased number of disarrayed
cristae andmitochondrial swelling [39,47]. Nevertheless, besides changes
in the levels of mitoﬁlin, no notorious ultrastructural evidence of T1DM-
induced cristae disorganization was observed (Fig. S1).
In conclusion, data from our study indicate that in an animal model
for prolonged severe hyperglycaemia that mimics uncontrolled type 1
diabetes in humans, the impaired IMF mitochondria functionality ob-
served in gastrocnemius is associated with decreased mitochondrialssion and in the mitochondrial protein carbonylation levels (D). Representative immu-
dard deviation. (*pb0.05vs CONT; **pb0.01vs CONT).
1197AI. Padrão et al. / Biochimica et Biophysica Acta 1822 (2012) 1189–1197PQC activity and the subsequent accumulation of damaged proteins. For
theﬁrst time, our data highlighted the T1DM-related down-regulation of
AAA proteases, namely the membranar paraplegin and the matrix Lon
protease. A deeper understanding of the involvement of these AAA pro-
teases in the PQC regulation of mitochondrial biogenesis would possibly
contribute to a better design of preventive and/or therapeutic counter-
measures against type 1 diabetes-related muscular complications.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.bbadis.2012.04.009.
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